Project Aim(s): To determine the effect(s) of CSF from Alzheimer's disease (AD) patients on cerebroids cultured healthy human iPSCs and to identify the mediator(s) of AD-CSF-mediated pathology.
Project Aim(s): To utilise brain organoids to investigate the aetiology of Alzheimer's disease.
Project Aim(s): To determine if the ApoE stimulator, bexarotene, can restore dysregulated calcium homeostasis in hippocampal neurons from transgenic AD mice.
Project Aim(s): To develop and promote resilience in family carers of people with dementia.
Alzheimer’s and Parkinson’s diseases (AD and PD) are the two most common neurodegenerative conditions. They cause major costs for society and suffering and death for millions of patients around the globe. In Europe, more than 8 million individuals have AD or PD. Current treatments are symptomatic but do not stop the underlying disease process. Using biomarkers, we can detect biochemical changes that show when neurons start to die. There are also biochemical tests for brain changes that are specific to AD and PD.
Project Aim(s): To determine the role of neuroinflammation in driving neurodegeneration.
Project Aim(s):
The project has various complementary aims: (a) research on normal ageing and Alzheimer's disease using MRI-based methods, (b) develop training programmes in neuroimaging in dementia, (c) develop greater understanding of the use of neuroimaging by clinicians for diagnosis of Alzheimer's disease, (d) technology transfer between centres.
Project Aim(s): The objective is the assessment of the impact of alterations of white matter tract integrity on effective connectivity in the neural network underpinning working memory. Using brain imaging data it will examine the associations between brain structure and function in young and older healthy participants and how normal ageing alters the relationship between structure and function.
Amyotrophic Lateral Sclerosis (ALS) is a terminal neuro-degenerative disorder of adults, typically having rapid progression and involving both motor and cognitive function. ALS exhibits considerable heterogeneity of both symptom profile and progression. Nevertheless, median survival is typically under three years from disease onset. ALS is the most common motor neurone disease in adults, with an incidence of 2 to 3 per 100,000 in Europe.